Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 166. Отображено 100.
25-05-2017 дата публикации

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Номер: US20170144971A1
Автор: Michael D. BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason A. DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian M. FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael W. GRIBBLE, Jr., Darin J. GUSTIN, Julie A. HEATH, Xin HUANG, XianYun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, SuJen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan D. LOW, Brian S. LUCAS, Zhihua MA, Lawrence R. MCGEE, Joel MCINTOSH, Dustin L. MCMINN, Julio C. MEDINA, Jeffrey Thomas MIHALIC, Steven H. OLSON, Yosup REW, Phillip M. ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, BARTBERGER MICHAEL D, GONZALEZ BUENROSTRO ANA, BECK HILARY PLAKE, CHEN XIAOQI, CONNORS RICHARD VICTOR, DEIGNAN JEFFREY, DUQUETTE JASON A, EKSTEROWICZ JOHN, FISHER BENJAMIN, FOX BRIAN M, FU JIASHENG, FU ZICE, GONZALEZ LOPEZ DE TURISO FELIX, GRIBBLE JR MICHAEL W, GUSTIN DARIN J, HEATH JULIE A, HUANG XIN, JIAO XIANYUN, JOHNSON MICHAEL G, KAYSER FRANK, KOPECKY DAVID JOHN, LAI SUJEN, LI YIHONG, LI ZHIHONG, LIU JIWEN, LOW JONATHAN D, LUCAS BRIAN S, MA ZHIHUA, MCGEE LAWRENCE R, MCINTOSH JOEL, MCMINN DUSTIN L, MEDINA JULIO C, MIHALIC JEFFREY THOMAS, OLSON STEVEN H, REW YOSUP, ROVETO PHILLIP M, SUN DAQING, WANG XIAODONG, WANG YINGCAI, YAN XUELEI, YU MING, ZHU JIANG, BARTBERGER Michael D., GONZALEZ BUENROSTRO Ana, BECK Hilary Plake, CHEN Xiaoqi, CONNORS Richard Victor, DEIGNAN Jeffrey, DUQUETTE Jason A., EKSTEROWICZ John, FISHER Benjamin, FOX Brian M., FU Jiasheng, FU Zice, GONZALEZ LOPEZ DE TURISO Felix, GRIBBLE, Jr. Michael W., GUSTIN Darin J., HEATH Julie A., HUANG Xin, JIAO XianYun, JOHNSON Michael G., KAYSER Frank, KOPECKY David John, LAI SuJen, LI Yihong, LI Zhihong, LIU Jiwen, LOW Jonathan D., LUCAS Brian S., MA Zhihua, MCGEE Lawrence R., MCINTOSH Joel, MCMINN Dustin L., MEDINA Julio C., MIHALIC Jeffrey Thomas, OLSON Steven H., REW Yosup, ROVETO Phillip M., SUN Daqing, WANG Xiaodong, WANG Yingcai, YAN Xuelei, YU Ming, ZHU Jiang
Принадлежит: AMGEN INC.

The present invention provides MDM2 inhibitor compounds of Formula I, 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(H)RR claim 1 , —NRR claim 1 , phenyl or pyridine claim 1 , wherein the phenyl or the pyridyl substituted with one or more Ras allowed by valence.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein Re is H or methyl or ethyl.14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , wherein Re is H or methyl or ethyl.19. A compound claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , selected from:2-((3R,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxobutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-4-methyl-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5S,6R)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((R)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-1-((S)-2-tert-Butoxy-1-cyclopropyl-2-oxoethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-hydroxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-cyclopropyl-2-hydroxyethyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(cyclopropylmethoxy)butan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-methoxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-( ...

Подробнее
09-01-2014 дата публикации

PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

Номер: US20140011796A1
Принадлежит: Amgen Inc.

The present invention provides MDM inhibitor compounds of Formula I, 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(H)RR claim 1 , —NRR claim 1 , phenyl or pyridine claim 1 , wherein the phenyl or the pyridyl substituted with one or more Rx as allowed by valence.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein Re is H or methyl or ethyl.14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , wherein Re is H or methyl or ethyl.19. A compound claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , selected from:2-((3R,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxobutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-4-methyl-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5S,6R)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((R)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-1-((S)-2-tert-Butoxy-1-cyclopropyl-2-oxoethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-hydroxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-cyclopropyl-2-hydroxyethyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(cyclopropylmethoxy)butan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-methoxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5 ...

Подробнее
20-02-2014 дата публикации

METHOD AND APPARATUS FOR PROVIDING AN INTERACTIVE USER INTERFACE

Номер: US20140053109A1
Принадлежит: Beijing Xiaomi Technology Co., Ltd.

A method for providing an interactive user interface on a mobile terminal having a touch screen, including: displaying a content layer and a background layer corresponding to the content layer; detecting a contact event occurring on the screen of the mobile terminal and obtaining an operation command corresponding to the contact event; and executing an operation according to the obtained operation command; wherein the background layer is located below the content layer and is configured to display a scene as a background; and the content layer is configured to arrange at least a component for user interaction, a preset point of an icon corresponding to the component being set to correspond to a preset position of the content layer, and the preset position of the content layer being set to correspond to a preset position of the scene displayed by the background layer. 1. A method for providing an interactive user interface on a mobile terminal having a touch screen , comprising:displaying a content layer and a background layer corresponding to the content layer;detecting a contact event occurring on the screen of the mobile terminal and obtaining an operation command corresponding to the contact event; andexecuting an operation according to the obtained operation command;wherein the background layer is located below the content layer and is configured to display a scene as a background; andthe content layer is configured to arrange at least a component for user interaction, a preset point of an icon corresponding to the component being set to correspond to a preset position of the content layer, and the preset position of the content layer being set to correspond to a preset position of the scene displayed by the background layer, such that the icon matches the scene displayed by the background layer.2. The method of claim 1 , wherein when the background layer is a slideable background layer and the obtained command is a sliding command claim 1 , the executing of the ...

Подробнее
07-01-2016 дата публикации

CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

Номер: US20160002185A1
Принадлежит: Amgen Inc.

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor. 2. The compound of wherein X is O.3. The compound of wherein X is —S(═O)—.4. The compound of wherein Ris hydrogen.5. The compound of wherein Ris Calkyl.6. The compound of wherein Ris methyl.7. The compound of wherein Ris hydrogen.8. The compound of wherein Ris methyl.9. The compound of wherein Ris hydrogen.10. The compound of wherein Ris methyl.11. The compound of wherein Ris substituted Caryl.12. The compound of wherein Ris substituted phenyl.13. The compound of wherein Ris phenyl substituted with from 1 to 3 halo groups.14. The compound of wherein Ris phenyl substituted with a fluorine.15. The compound of wherein Ris phenyl substituted with a bromine.16. The compound of wherein Ris 4-chlorophenyl or 4-bromophenyl.17. The compound of wherein Ris substituted Caryl.18. The compound of wherein Ris substituted phenyl.19. The compound of wherein Ris phenyl substituted with from 1 to 3 halo groups.20. The compound of wherein Ris phenyl substituted with a fluorine.21. The compound of wherein Ris phenyl substituted with a bromine.22. The compound of wherein Ris 4-chlorophenyl or 4-bromophenyl.23. The compound of wherein Ris 3-chlorophenyl or 3-bromophenyl.24. The compound of wherein Ris hydrogen.25. The compound of wherein Ris Calkyl.26. The compound of wherein Ris —CHC(═O)OH.27. The compound of wherein Ris —CHphenyl.28. The compound of wherein Ris —CHphenyl substituted with from 1 to 3 substituents independently selected from Calkyl claim 1 , halo claim 1 , —(CRR)halo claim 1 , —OCalkyl claim 1 , —OCF claim 1 , —OCFH claim 1 , —OCFH claim 1 , —CN claim 1 , —S(═O)CF claim 1 , —C(═O)NRR claim 1 , —C(═O)OR claim 1 , Caryl claim ...

Подробнее
07-01-2021 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20210002324A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism. 2. The compound of or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris hydrogen claim 1 , alkyl claim 1 , haloalkyl claim 1 , hydroxy claim 1 , halo claim 1 , carbocyclyl claim 1 , or heteroalkyl.3. The compound of either of or or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris Calkyl or hydrogen.4. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris methyl.5. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris methyl and Rand Rare H.6. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris H.7. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein R claim 1 , R claim 1 , and Rare H.8. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein ring A is monocyclic heteroaryl or monocyclic aryl.9. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein ring A is phenyl claim 1 , pyridinyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , or pyridazinyl.10. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or ...

Подробнее
10-01-2019 дата публикации

TOUCH PANEL AND METHOD FOR MANUFACTURING THE SAME, DISPLAY APPARATUS

Номер: US20190012026A1
Принадлежит:

The present disclosure provides a touch panel and a method for manufacturing the same, and a display apparatus. The display panel includes a substrate, a touch electrode provided in a touch region of the substrate, and a plurality of signal transmission lines provided in a non-touch wiring region of the substrate, the non-touch wiring region of the substrate is located in a bezel of the touch panel, the signal transmission lines are coupled to the touch electrode for transmitting a touch signal, the signal transmission lines in the non-touch wiring region are arranged in at least two layers overlapping with each other, and the signal transmission lines of adjacent layers are insulated from each other. 1. A touch panel , comprising a substrate , a touch electrode provided in a touch region of the substrate , and a plurality of signal transmission lines provided in a non-touch wiring region of the substrate , the non-touch wiring region of the substrate is located in a bezel of the touch panel , the signal transmission lines are coupled to the touch electrode for transmitting a touch signal , the signal transmission lines in the non-touch wiring region are arranged in at least two layers overlapping with each other , and the signal transmission lines of adjacent layers are insulated from each other.2. The touch panel of claim 1 , wherein the touch electrode comprises a plurality of first electrode strips and a plurality of second electrode strips claim 1 , the first electrode strips intersect with and are insulated from the second electrode strips claim 1 , the signal transmission lines are coupled to the first electrode strips and the second electrode strips one to one claim 1 , a portion of the signal transmission lines are arranged in a first layer in the non-touch wiring region claim 1 , another portion of the signal transmission lines are arranged in a second layer in the non-touch wiring region claim 1 , and a first insulation layer is interposed between the ...

Подробнее
21-01-2021 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20210017219A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. 2. The compound of or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein R is hydrogen claim 1 , alkyl claim 1 , haloalkyl claim 1 , hydroxy claim 1 , halo claim 1 , carbocyclyl claim 1 , or heteroalkyl.3. The compound of or or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris Calkyl or hydrogen.4. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris methyl.5. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris H.6. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein ring A is monocyclic heteroaryl or monocyclic aryl.7. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein ring A is phenyl claim 1 , pyridinyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , or pyridazinyl.8. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein ring A is phenyl.9. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris Calkyl.10. The compound of any one of - or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris Calkyl.11. The compound of any ...

Подробнее
21-01-2021 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20210017220A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism. 25.-. (canceled)6. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein each Ris independently —NRR claim 1 , halo claim 1 , alkyl claim 1 , carbocyclyl claim 1 , alkoxy claim 1 , or —CN.7. (canceled)8. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Rand Rare each independently —H claim 1 , alkyl claim 1 , or —S(O)R.9. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein{'sup': 4', '5', '6, 'sub': '2', 'Rand Rattached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted 4-, 5-, or 6-membered ring heterocycle additionally containing 0-3 heteroatoms selected from the group consisting of —O—, —NH—, —NR—, —S—, and —S(O)—; and'}{'sup': '6', 'Ris alkyl.'}10. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris alkyl claim 1 , carbocyclyl claim 1 , or fluoroalkyl.11. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein Ris alkyl claim 1 , carbocyclyl claim 1 , optionally substituted aryl claim 1 , optionally substituted aralkyl claim 1 , or optionally substituted heterocyclyl.1213.-. (canceled)14. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or ...

Подробнее
28-01-2021 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20210023095A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism. 2. The compound of or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof claim 1 , wherein{'sup': 1', '3', '6', '3', '3', '4', '3', '6', '3', '3', '4', '3', '3', '4', '3', '4', '6, 'sub': 2', '2', '2', '2', '2', '2, 'Ris —NRS(O)R, —NRS(O)NRR, -alkyNRS(O)R, -alkyNRS(O)NRR, —NRaralkyl, —C(O)NRR, —S(O)NRR, or —S(O)R;'}{'sup': 3', '4', '10', '6, 'sub': 2', '2, 'Rand Rare each independently —H, optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, —C(O)N(R), or —S(O)R;'}{'sup': 3', '4, 'or Rand Rattached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted 3-, 4-, 5-, or 6-membered heterocycle;'}{'sup': '5', 'Ris optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl;'}{'sup': '6', 'Ris optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;'}{'sup': 7', '8', '5', '3', '4', '3', '4, 'Rand Rare each independently —H, optionally substituted alkyl, fluoroalkyl, halo, —OR, —NRR, —C(O)NRR, —CN, optionally substituted carbocyclyl, or optionally substituted carbocyclylalkyl;'}{'sup': 7', '8', '6, 'sub': '2', 'or Rand Rare taken ...

Подробнее
24-02-2022 дата публикации

CD73 INHIBITORS

Номер: US20220054512A1
Принадлежит:

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': '8', 'sub': ['1', '6'], '#text': 'Ris hydrogen or C-Calkyl.'}3. The compound of or claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': '8', '#text': 'Ris hydrogen.'}4. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': ['9', '10'], 'sub': ['1', '6'], '#text': 'Rand Rare each independently hydrogen or C-Calkyl.'}5. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': ['9', '10'], '#text': 'Rand Rare each hydrogen.'}6. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': ['11', '12'], '#text': 'X is —CRR—; and'}{'sup': ['11', '12'], '#text': 'Rand Rare each independently hydrogen or halogen.'}7. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:X is —O—.9. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:n, m, and p, are each 1;{'sup': ['1', '2', '3', '13', '14'], '#text': 'Y, Y, and Yare independently —O— or —CRR—; and'}{'sup': ['13', '14'], 'sub': ['1', '6'], '#text': 'Rand Rare each independently hydrogen, halogen, or C-Calkyl.'}10. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or ...

Подробнее
18-02-2021 дата публикации

ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS

Номер: US20210047344A1
Принадлежит: Amgen Inc.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 3. The compound of claim 1 , wherein Ris Cl.5. The compound of claim 4 , wherein Ris H.6. The compound of claim 5 , wherein Ris H.7. The compound of claim 1 , wherein Ris H.8. The compound of claim 1 , wherein Ris H.9. The compound of claim 1 , wherein Ris H.10. The compound of claim 1 , wherein Ris H.12. The compound of claim 1 , wherein Ris —COOH.13. The compound of claim 1 , wherein Ris —OH.14. The compound of claim 1 , wherein Ris —OH.17. The compound of claim 16 , wherein Ris CH.18. The compound of claim 16 , wherein Ris H.19. The compound of claim 16 , wherein Ris H.20. The compound of claim 16 , wherein Ris H.21. The compound of claim 16 , wherein Ris H.23. The compound of claim 22 , wherein Ris —COOH.24. The compound of claim 16 , wherein Ris —OH.27. A pharmaceutical composition comprising the compound of claim 1 , or the pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier or diluent.28. A method of treating cancer claim 1 , the method comprising: administering to a patient in need thereof a therapeutically effective amount of the compound of or the pharmaceutically acceptable salt thereof.29. The method of claim 28 , wherein the cancer is a hematologic malignancy.30. The method of claim 28 , wherein the cancer is selected from the group consisting of breast cancer claim 28 , colorectal cancer claim 28 , skin cancer claim 28 , melanoma claim 28 , ovarian cancer claim 28 , kidney cancer claim 28 , lung cancer claim 28 , non-small cell ...

Подробнее
18-02-2021 дата публикации

Cd73 inhibitors

Номер: US20210047359A1
Принадлежит: Oric Pharmaceuticals Inc

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Подробнее
20-02-2020 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20200055892A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. 155.-. (canceled)57. The method of claim 56 , wherein the cancer is breast cancer claim 56 , ovarian cancer claim 56 , or prostate cancer.58. The method of claim 56 , wherein the cancer is chemo-resistant.59. The method of claim 56 , wherein the cancer is castration resistant prostate cancer.60. The method of claim 56 , further comprising administering a second therapeutic agent to the subject selected from an androgen receptor inhibitor claim 56 , cisplatin claim 56 , carboplatin claim 56 , paclitaxel claim 56 , gemcitabine claim 56 , doxorubicin claim 56 , camptothecin claim 56 , topotecan claim 56 , an anti-PD-L1 agent or an anti-PD1 agent claim 56 , and any combinations thereof.61. The method of claim 56 , further comprising administering nab-paclitaxel or enzalutamide.63. The method of claim 62 , wherein the cancer is breast cancer claim 62 , ovarian cancer claim 62 , or prostate cancer.64. The method of claim 62 , wherein the cancer is chemo-resistant.65. The method of claim 62 , wherein the cancer is castration resistant prostate cancer.66. The method of claim 62 , further comprising administering a second therapeutic agent to the subject selected from an androgen receptor inhibitor claim 62 , cisplatin claim 62 , carboplatin claim 62 , paclitaxel claim 62 , gemcitabine claim 62 , doxorubicin claim 62 , camptothecin claim 62 , topotecan claim 62 , an anti-PD-L1 agent or an anti-PD1 agent claim 62 , and any combinations thereof.67. The method of claim 62 , further comprising administering nab-paclitaxel paclitaxel or enzalutamide.69. The method of ...

Подробнее
17-03-2022 дата публикации

GLUCOCORTICOID RECEPTOR MODULATORS

Номер: US20220079924A1
Принадлежит:

Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:{'sup': '2', 'Ris hydrogen.'}3. The compound of or claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:{'sup': '3', 'sub': 1', '6, 'each Ris independently halogen or C-Calkyl.'}4. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:n is 0.5. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:{'sup': '5', 'sub': 1', '6, 'each Ris independently halogen or C-Calkyl.'}6. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:m is 0.7. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:X is a bond.8. The compound of any one of - claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:{'sup': '7', 'sub': '2', 'X is —C(R)—.'}9. The compound of any one of - or claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or isotopic variant thereof claim 1 , wherein:{'sup': 7', '7a, 'sub': 1', '6', '1', '6, 'each Ris independently hydrogen, C-Calkyl, C-Chaloalkyl, cycloalkyl, or heterocycloalkyl, wherein the ...

Подробнее
28-02-2019 дата публикации

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Номер: US20190062276A1
Принадлежит:

The present invention provides MDM2 inhibitor compounds of Formula I, 130-. (canceled)31. A pharmaceutical composition comprising a compound of 2-(3R ,5R ,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid , or a pharmaceutically acceptable salt thereof.32. The pharmaceutical composition of claim 31 , further comprising microcrystalline cellulose.33. The pharmaceutical composition of claim 31 , further comprising lactose.34. The pharmaceutical composition of claim 31 , further comprising carboxymethylcellulose.35. The pharmaceutical composition of claim 31 , further comprising magnesium stearate.36. The pharmaceutical composition of claim 31 , in a dosage form formulated for topical administration.37. The pharmaceutical composition of claim 36 , wherein the dosage form is an ointment.38. The pharmaceutical composition of claim 36 , wherein the dosage form is spray.39. The pharmaceutical composition of claim 36 , wherein the dosage form is inhalants.40. The pharmaceutical composition of is in a dosage form for oral administration.41. The pharmaceutical composition of claim 40 , wherein the dosage form is tablets.42. The pharmaceutical composition of claim 40 , wherein the dosage form is capsules.43. The pharmaceutical composition of claim 31 , further comprising a pharmaceutically active agent selected from the group consisting of dronabinol claim 31 , granisetron claim 31 , metoclopramide claim 31 , ondansetron claim 31 , and prochlorperazine claim 31 , and a pharmaceutically acceptable salt thereof.44. A method of treating nausea in a subject in need thereof claim 43 , the method comprising administering to the subject an effective amount of the pharmaceutical composition of .451. A method of treating cancer in a subject in need thereof claim 43 , the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim claim 43 , wherein the ...

Подробнее
26-03-2020 дата публикации

Cd73 inhibitors

Номер: US20200093844A1
Принадлежит: Oric Pharmaceuticals Inc

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Подробнее
02-06-2022 дата публикации

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Номер: US20220169611A1
Принадлежит:

The present invention provides MDM2 inhibitor compounds of Formula I, 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(H)RR claim 1 , —NRR claim 1 , phenyl or pyridine claim 1 , wherein the phenyl or the pyridyl substituted with one or more Ras allowed by valence.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein Re is H or methyl or ethyl.14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , wherein Re is H or methyl or ethyl.19. A compound claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , selected from:2-((3R,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxobutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-4-methyl-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5S,6R)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((R)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-1-((S)-2-tert-Butoxy-1-cyclopropyl-2-oxoethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-hydroxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-cyclopropyl-2-hydroxyethyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(cyclopropylmethoxy)butan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-methoxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-( ...

Подробнее
23-04-2015 дата публикации

METHOD AND TERMINAL DEVICE FOR ADJUSTING WIDGET

Номер: US20150113431A1
Принадлежит:

The present disclosure discloses a method and a terminal device for adjusting a widget. The method includes: acquiring a size value of the widget on an interface of a terminal device after switching a grid configuration of the interface from a first grid configuration to a second grid configuration; and determining the number of grids occupied by the widget according to size values of each grid in the second grid configuration. 1. A method for adjusting a widget , comprising:acquiring a size value of the widget on an interface of a terminal device after switching a grid configuration of the interface from a first grid configuration to a second grid configuration; anddetermining the number of grids occupied by the widget according to size values of each grid in the second grid configuration.2. The method according to claim 1 , wherein switching the grid configuration of the interface from the first grid configuration to the second grid configuration comprises:acquiring a selected second grid configuration after receiving a request for switching the grid configuration of the interface;removing the first grid configuration; andadopting the second grid configuration as the current grid configuration of the interface.3. The method according to claim 1 , wherein determining the number of grids occupied by the widget according to the size values of each grid in the second grid configuration comprises:acquiring a length ratio by comparing a length of the widget with a length of a grid;acquiring a width ratio by comparing a width of the widget with a width of the grid; andobtaining the number of latitudinal grids occupied by the widget according to the length ratio and the number of longitudinal grids occupied by the widget according to the width ratio.4. The method according to claim 1 , wherein the method further comprises:adjusting a location of the widget on the interface according to the number of grids occupied by the widget if the widget is located on the interface; ...

Подробнее
29-04-2021 дата публикации

Glucocorticoid receptor modulators

Номер: US20210122730A1
Принадлежит: Oric Pharmaceuticals Inc

Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.

Подробнее
19-05-2016 дата публикации

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Номер: US20160137667A1
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
21-05-2015 дата публикации

METHOD AND TERMINAL FOR RESPONDING TO SLIDING OPERATION

Номер: US20150143286A1
Автор: Li Weixing, SUN Daqing, Zhu Cai
Принадлежит:

There is provided a method for responding to a sliding operation for use in a terminal having a touch screen and operating on an operating system including a system process, an application process, and an interface delivery process, wherein the application process is configured to draw a display content in a size larger than a size of the touch screen. The method includes: when the system process detects the sliding operation, acquiring a sliding distance and a sliding direction of the sliding operation; transmitting the sliding distance and the sliding direction of the sliding operation to each of the application process and the interface delivery process; when the interface delivery process receives the sliding distance and the sliding direction, moving a display window in the sliding direction, according to the sliding distance; and controlling the touch screen to display a display content corresponding to the moved display window. 1. A method for responding to a sliding operation for use in a terminal having a touch screen and operating on an operating system including a system process , an application process , and an interface delivery process , wherein the application process is configured to draw a display content in a size larger than a size of the touch screen , the method comprising:when the system process detects the sliding operation, acquiring a sliding distance and a sliding direction of the sliding operation;transmitting, by the system process, the sliding distance and the sliding direction of the sliding operation to each of the application process and the interface delivery process;when the interface delivery process receives the sliding distance and the sliding direction, moving a display window in the sliding direction, according to the sliding distance; andcontrolling, by the interface delivery process, the touch screen to display a display content corresponding to the moved display window.2. The method according to claim 1 , further comprising: ...

Подробнее
17-06-2021 дата публикации

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

Номер: US20210179560A1
Принадлежит:

The present invention provides MDM2 inhibitor compounds of Formula I, 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(H)RR claim 1 , —NRR claim 1 , phenyl or pyridine claim 1 , wherein the phenyl or the pyridyl substituted with one or more Ras allowed by valence.12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof claim 11 , wherein Re is H or methyl or ethyl.14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , wherein Re is H or methyl or ethyl.19. A compound claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , selected from:2-((3R,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5R,6S)-1-((S)-1-tert-butoxy-1-oxobutan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxobutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-4-methyl-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3S,5S,6R)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((R)-1-ethoxy-1-oxopentan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-1-((S)-2-tert-Butoxy-1-cyclopropyl-2-oxoethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-hydroxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-cyclopropyl-2-hydroxyethyl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(cyclopropylmethoxy)butan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-methoxybutan-2-yl)-2-oxopiperidin-3-yl)acetic acid;2-((3R,5R,6S)-5-( ...

Подробнее
21-08-2014 дата публикации

Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer

Номер: US20140235629A1
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
15-07-2021 дата публикации

CD73 INHIBITORS

Номер: US20210214387A1
Принадлежит:

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases. 14. The method of claim 1 , wherein the cancer is leukemia.15. The method of claim 14 , wherein the leukemia is acute lymphocytic leukemia claim 14 , chronic lymphocytic leukemia claim 14 , myelocytic leukemia claim 14 , refractory anemia claim 14 , preleukemia claim 14 , chronic myelomonocytic leukemia (CMML) claim 14 , or hairy cell leukemia.16. The method of claim 1 , wherein the cancer is lymphoma.17. The method of claim 16 , wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.18. The method of claim 1 , wherein the cancer is multiple myeloma.19. The method of claim 18 , wherein the multiple myeloma is smoldering multiple myeloma claim 18 , non-secretory myeloma claim 18 , osteosclerotic myeloma claim 18 , plasma cell leukemia claim 18 , or solitary plasmacytoma.20. The method of claim 19 , wherein the multiple myeloma is smoldering multiple myeloma.21. The method of claim 19 , wherein the multiple myeloma is non-secretory myeloma.22. The method of claim 19 , wherein the multiple myeloma is osteosclerotic myeloma.23. The method of claim 19 , wherein the multiple myeloma is plasma cell leukemia.24. The method of claim 19 , wherein the multiple myeloma is solitary plasmacytoma. This application is a continuation of U.S. application Ser. No. 17/114,993, filed Dec. 8, 2020, which is a continuation of U.S. application Ser. No. 17/083,871, filed Oct. 29, 2020, which claims the benefit of U.S. Application Ser. No. 62/928,138, filed Oct. 30, 2019, U.S. Application Ser. No. 62/987,806, filed Mar. 10, 2020, and U.S. Application Ser. No. 63/088,646 filed Oct. 7, 2020, which are hereby incorporated by reference in their entirety.A need exists in the art for an effective treatment of cancer, infections, and neurodegenerative diseases.Provided ...

Подробнее
22-07-2021 дата публикации

Refractive Index Adjustment Structure, Color Filter Substrate, Display Panel and Display Apparatus

Номер: US20210223643A1
Принадлежит:

Disclosed are a refractive index adjustment structure, a color filter substrate, a display panel and a display apparatus. The refractive index adjustment structure includes an adjustment layer and at least one electrode layer. The adjustment layer and the at least one electrode layer are provided in a stacked manner. The at least one electrode layer is configured to be loaded with an electric signal, and the electric signal is capable of adjusting a refractive index of the adjustment layer. 1. A refractive index adjustment structure , comprising an adjustment layer and at least one electrode layer , wherein the adjustment layer and the at least one electrode layer are provided in a stacked manner , and the at least one electrode layer is configured to be loaded with an electric signal , the electric signal being capable of adjusting a refractive index of the adjustment layer.2. The refractive index adjustment structure of claim 1 , wherein the at least one electrode layer comprises a first electrode layer claim 1 , and the adjustment layer is a first adjustment layer doped with magnetic particles; andthe first electrode layer is configured to generate a magnetic field based on the electric signal, and the magnetic field is capable of adjusting distribution of the magnetic particles in the first adjustment layer in a direction perpendicular to the first electrode layer.3. The refractive index adjustment structure of claim 2 , wherein in response to the electric signal loaded onto the first electrode layer claim 2 , a portion of the first adjustment layer close to the first electrode layer has a refractive index larger than a refractive index of a portion of the first adjustment layer away from the first electrode layer.4. The refractive index adjustment structure of claim 2 , wherein in the absence of the electric signal in the first electrode layer claim 2 , the magnetic particles are uniformly distributed in the first adjustment layer.5. The refractive index ...

Подробнее
22-07-2021 дата публикации

VIA HOLE STRUCTURE, MANUFACTURING METHOD THEREOF, ELECTRONIC DEVICE, AND DISPLAY DEVICE

Номер: US20210225738A1
Принадлежит:

A via hole structure includes: a first conductive layer, an interlayer insulating layer, and a second conductive layer that are sequentially arranged, wherein the interlayer insulating layer is provided with a via hole, the second conductive layer is overlapped with the first conductive layer by the via hole, and at least part of a surface, in contact with the second conductive layer, of the interlayer insulating layer is uneven. 1. A via hole structure , comprising:a first conductive layer, an interlayer insulating layer, and a second conductive layer that are sequentially arranged, wherein the interlayer insulating layer is provided with a via hole, the second conductive layer is overlapped with the first conductive layer by the via hole, and at least part of a surface, in contact with the second conductive layer, of the interlayer insulating layer is uneven.2. The via hole structure according to claim 1 , wherein an inner wall surface of the via hole is uneven.3. The via hole structure according to claim 1 , wherein a surface claim 1 , distal from the first conductive layer claim 1 , of the interlayer insulating layer is uneven.4. The via hole structure according to claim 1 , whereinthe uneven surface has a roughness in a value range of 0.05 d≤r≤0.15 d, where r represents the roughness, and d represents a thickness of the interlayer insulating layer.5. The via hole structure according to claim 4 , wherein r=0.05 d.6. The via hole structure according to claim 1 , wherein at least one of the first conductive layer and the second conductive layer is made of metal.7. The via hole structure according to claim 1 , whereinthe first conductive layer comprises a common electrode line, and the second conductive layer comprises a common electrode.8. A manufacturing method of a via hole structure claim 1 , comprising:forming a first conductive layer and an initial insulating layer sequentially;obtaining an interlayer insulating layer by forming a via hole on the initial ...

Подробнее
09-10-2014 дата публикации

METHOD AND DEVICE FOR ARRANGING ICONS

Номер: US20140304631A1
Принадлежит: Xiaomi Inc.

A method for a device to arrange icons displayed on a screen of the device includes creating a buffer region in a memory of the device; marking one or more icons selected by a user as one or more icons to be arranged; storing the icons to be arranged in the buffer region; and performing an arranging operation on the icons to be arranged that are stored in the buffer region, according to an arranging instruction from the user. 1. A method for a device to arrange icons displayed on a screen of the device , comprising:creating a buffer region in a memory of the device;marking one or more icons selected by a user as one or more icons to be arranged;storing the icons to be arranged in the buffer region; andperforming an arranging operation on the icons to be arranged that are stored in the buffer region, according to an arranging instruction from the user.2. The method according to claim 1 , before the creating of the buffer region claim 1 , further comprising:causing a desktop to enter an edit mode based on a user operation; andsetting a first predetermined area on the screen as a selecting area for selection by the user.3. The method according to claim 2 , wherein the creating of the buffer region claim 2 , the marking of the selected icons claim 2 , and the storing of the icons to be arranged comprise:detecting a click on a first icon on the desktop;in response to the detecting, creating the buffer region and setting the first predetermined area on the screen as a display area for the icons to be arranged;marking a plurality of icons selected by the user as the icons to be arranged; andstoring the icons to be arranged in the buffer region and displaying the icons to be arranged in the first predetermined area.4. The method according to claim 3 , further comprising:marking the plurality of icons selected by the user as the icons to be arranged and storing the icons to be arranged in the buffer region according to a sequence that the plurality of icons are selected by ...

Подробнее
23-10-2014 дата публикации

PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

Номер: US20140315895A1
Принадлежит:

The present invention provides MDM2 inhibitor compounds of Formula I, 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —C(H)RR claim 1 , —NRR claim 1 , phenyl or pyridine claim 1 , wherein the phenyl or the pyridyl substituted with one or more Ras allowed by valence.7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Re is H or methyl or ethyl.11. A compound claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , selected from:((3S,4R,6R)-4-(3-chlorophenyl)-3-(4-chlorophenyl)-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid;((3S,4R,6S)-4-(3-chlorophenyl)-3-(4-chlorophenyl)-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid;((3S,4R,6R)-4-(3-chlorophenyl)-3-(4-chlorophenyl)-6-methyl-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid; or((3S,4R,6S)-4-(3-chlorophenyl)-3-(4-chlorophenyl)-6-methyl-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid.12. A compound claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , selected from:(4-(3-chlorophenyl)-3-(4-chlorophenyl)-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid; or(4-(3-chlorophenyl)-3-(4-chlorophenyl)-6-methyl-1,1-dioxido-2-(2-propanyl)-1,2-thiazinan-6-yl)acetic acid.13. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , together with a pharmaceutically acceptable excipient claim 1 , diluent or carrier.14. A method of treating cancer in a subject in need of said treatment claim 1 , the method comprising administering to the subject an effective dosage amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof. The present invention relates to compounds that are MDM2 inhibitors that are useful as therapeutic agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.p53 is a tumor suppressor and ...

Подробнее
18-07-2019 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20190218246A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. 2. A pharmaceutical composition comprising the compound of and at least one pharmaceutically acceptable excipient.3. A method for treating or preventing cancer in a subject in need thereof claim 1 , the method comprising administering a therapeutically effective amount of the compound of to the subject in need thereof.4. The method of claim 3 , wherein the cancer is triple negative breast cancer claim 3 , high grade serous ovarian cancer claim 3 , castration resistant prostate cancer claim 3 , or doubly resistant prostate cancer.5. The method of claim 3 , wherein the cancer is non-small cell lung cancer.6. The method of claim 3 , further comprising administering a second therapeutic agent to the subject selected from an androgen receptor inhibitor claim 3 , cisplatin claim 3 , carboplatin claim 3 , paclitaxel claim 3 , gemcitabine claim 3 , doxorubicin claim 3 , camptothecin claim 3 , topotecan claim 3 , an anti-PD-L1 agent or an anti-PD1 agent claim 3 , and any combinations thereof.7. A method for treating a hypercortisolism disease or disorder in a subject claim 1 , the method comprising administering a therapeutically effective amount of the compound of .9. A pharmaceutical composition comprising the pharmaceutically acceptable salt of the compound of and at least one pharmaceutically acceptable excipient.10. A method for treating or preventing cancer in a subject in need thereof claim 8 , the method comprising administering a therapeutically effective amount of the pharmaceutically acceptable salt of the compound of to the subject in need thereof.11. ...

Подробнее
30-10-2014 дата публикации

Method for displaying an icon and terminal device thereof

Номер: US20140325447A1
Автор: Daqing Sun, FAN JIN, YING Wang
Принадлежит: Xiaomi Inc

The present disclosure discloses a method for displaying an icon in a terminal device and the terminal device thereof. The method includes monitoring an implementation of an event which controls a display of the icon; determining animation display parameters according to properties of the icon, if the implementation of the event which controls the display of the icon is detected; and controlling the icon to be displayed in an animated manner in accordance with the animation display parameters. The present disclosure provides more enriched display effects of the icon.

Подробнее
08-10-2015 дата публикации

METHOD, APPARATUS, AND TERMINAL DEVICE FOR CONTROLLING DISPLAY OF APPLICATION INTERFACE

Номер: US20150286356A1
Автор: Li Weixing, SUN Daqing, Zhu Cai
Принадлежит:

A method for controlling display of an application interface is provided. The method includes: detecting a first screen-touching operation; detecting a second screen-touching operation after detecting the first screen-touching operation; determining a movement direction and a movement distance of the second screen-touching operation; and causing the display of the application interface to be moved based on the movement direction and the movement distance of the second screen-touching operation. 1. A method for controlling display of an application interface , comprising:detecting a first screen-touching operation;detecting a second screen-touching operation after detecting the first screen-touching operation;determining a movement direction and a movement distance of the second screen-touching operation; andcausing the display of the application interface to be moved based on the movement direction and the movement distance of the second screen-touching operation.2. The method according to claim 1 , wherein the display of the application interface is moved along the movement direction of the second screen-touching operation over a distance equal to the movement distance of the second screen-touching operation.3. The method according to claim 1 , wherein the application interface includes two or more user interface pages for displaying on a terminal device.4. The method according to claim 1 , wherein determining the movement direction of the second screen-touching operation comprises:if an angle between a horizontal direction and a direction formed by start-point coordinates and end-point coordinates of the second screen-touching operation is less than or equal to a preset angle, determining the movement direction of the second screen-touching operation to be the horizontal direction; andif the angle between the horizontal direction and the direction formed by the start-point coordinates and the end-point coordinates of the second screen-touching operation is greater ...

Подробнее
09-12-2021 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20210379084A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism. 158.-. (canceled)60. The method of claim 59 , wherein in the compound of Formula (I) claim 59 , or a pharmaceutically acceptable salt thereof claim 59 ,{'sup': 1', '3', '6', '3', '3', '4', '3', '6', '3', '3', '4', '3', '4', '3', '4', '6, 'sub': 2', '2', '2', '2', '2', '2, 'Ris —NRS(O)R, —NRS(O)NRR, -alkylNRS(O)R, -alkylNRS(O)NRR, —C(O)NRR, —S(O)NRR, or —S(O)R;'}{'sup': 3', '4', '10', '6, 'sub': 2', '2, 'Rand Rare each independently —H, optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, —C(O)N(R), or —S(O)R;'}{'sup': 3', '4, 'or Rand Rattached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted 3-, 4-, 5-, or 6-membered heterocycle;'}{'sup': '5', 'Ris optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl;'}{'sup': '6', 'Ris optionally substituted alkyl, fluoroalkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;'}{'sup': 7', '8', '5', '3', '4', '3', '4, 'Rand Rare each independently —H, optionally substituted alkyl, fluoroalkyl, halo, —OR, —NRR, —C(O)NRR, —CN, optionally substituted carbocyclyl, or optionally substituted carbocyclylalkyl;'}{'sup': 7', '8', '6, 'sub': '2', 'or ...

Подробнее
17-09-2020 дата публикации

INHIBITORS OF GLUCOCORTICOID RECEPTOR

Номер: US20200291058A1
Принадлежит:

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
13-12-2018 дата публикации

Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer

Номер: US20180354918A1
Принадлежит: AMGEN INC

wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
05-11-2020 дата публикации

CD73 INHIBITORS

Номер: US20200347090A1
Принадлежит:

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases. 2. The compound of claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': 45', '46, 'sub': 1', '6, 'Rand Rare each independently hydrogen, halogen, or C-Calkyl; and'}v2 is 1 or 2.3. The compound of or claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': 45', '46, 'Rand Rare each hydrogen; and'}v2 is 1.4. The compound of any one of - claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': '1', 'Qis CW; and'}{'sup': '2', 'Qis N.'}5. The compound of any one of - pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': '1', 'Qis N; and'}{'sup': '2', 'Qis N.'}6. The compound of any one of - claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': a', 'c', 'd', 'b', 'c', 'd', '3, 'sub': 1', '6, 'W is hydrogen, halogen, —CN, —OH, —OR, —NRR, —C(═O)OR, —C(═O)NRR, C-Calkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl, is independently optionally substituted with one, two, or three R.'}7. The compound of any one of - or claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:{'sup': a', 'c', 'd, 'sub': 1', '6', '1', '6, 'W is hydrogen, halogen, —OH, —OR, —NRR, C-Calkyl, or C-Chaloalkyl.'}8. The compound of any one of - or or claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof claim 1 , wherein:W is hydrogen.9. The compound of any one of - claim 1 , pharmaceutically acceptable salt claim 1 , solvate claim 1 , or ...

Подробнее
17-04-2003 дата публикации

Imidazole derivates as anti-inflammatory agents

Номер: WO2003030902A1
Принадлежит: Tularik Inc.

Compounds (I), pharmaceutical compositions thereof are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. All definitions are as in the application.

Подробнее
29-12-2022 дата публикации

Cd73 inhibitors

Номер: US20220411459A1
Принадлежит: Oric Pharmaceuticals Inc

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Подробнее
21-12-2006 дата публикации

Arylsulfonamides and uses as hydroxysteroid dehydrogenase

Номер: WO2005118538A3

Arylsulfonamide compounds of formula (I) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders.

Подробнее
09-06-2011 дата публикации

Arylsulfonamides and uses as hydroxysteroid dehydrogenase

Номер: AU2005250336B2
Принадлежит: AMGEN INC

Подробнее
16-11-2010 дата публикации

Arylsulfonamides and uses related thereto

Номер: US7834047B2
Принадлежит: AMGEN INC

Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:

Подробнее
24-02-2009 дата публикации

Arylsulfonamides and uses related thereto

Номер: US7495012B2
Принадлежит: AMGEN INC

Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:

Подробнее
13-12-2011 дата публикации

Aniline sulfonamide derivatives and their uses

Номер: US8076376B2
Принадлежит: AMGEN INC

Aniline sulfonamide derivatives according to formula I have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and L are set forth in the description.

Подробнее
08-06-2011 дата публикации

Imidazole derivatives as antiinflammatory agents

Номер: EP1434579B1
Принадлежит: AMGEN INC

Compounds (I), pharmaceutical compositions thereof are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. All definitions are as in the application.

Подробнее
04-01-2011 дата публикации

Imidazole derivates as anti-inflammatory agents

Номер: CA2458533C
Принадлежит: AMGEN INC

Compounds of formula (I): (see formula I) where R1, R2, Y, Z1 and Z2 are as defined herein, and pharmaceutical compositions thereof are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation.

Подробнее
07-11-2006 дата публикации

Benzimidazole derivatives

Номер: US7132438B2
Принадлежит: AMGEN INC

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Подробнее
03-11-2011 дата публикации

IMIDAZOL DERIVATIVES AS ANTI-INFLAMMATORY AGENTS.

Номер: ES2367422T3
Принадлежит: AMGEN INC

Un compuesto de fórmula (I): o una de sus sales farmacéuticamente aceptables; en la que R1 es cicloalquilo (C3-C8), no sustituido o sustituido; R2 es arilo o heteroarilo, no sustituido o sustituido; Y es C(O); y Z1 y Z2 se combinan para formar un anillo aromático de 6 miembros condensado adicional, no sustituido o sustituido. A compound of formula (I): or one of its pharmaceutically acceptable salts; wherein R1 is cycloalkyl (C3-C8), unsubstituted or substituted; R2 is aryl or heteroaryl, unsubstituted or substituted; Y is C (O); and Z1 and Z2 combine to form an additional condensed, unsubstituted or substituted 6-membered aromatic ring.

Подробнее
22-12-2009 дата публикации

Benzimidazole derivatives

Номер: US7635774B2
Принадлежит: AMGEN INC

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Подробнее
25-02-2010 дата публикации

Benzimidazole derivatives

Номер: US20100048565A1

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Подробнее
31-07-2003 дата публикации

Benzimidazole derivatives

Номер: US20030144286A1
Принадлежит: Tularik Inc

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Подробнее
15-02-2007 дата публикации

Benzimidazole derivatives

Номер: US20070037803A1
Принадлежит: Amgen SF LLC

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.

Подробнее
22-04-2003 дата публикации

Imidazole derivates as antiinflammatory agents

Номер: AU2002332099B8
Принадлежит: AMGEN INC

Подробнее
17-04-2003 дата публикации

Imidazole derivates as anti-inflammatory agents

Номер: CA2458533A1

Compounds (I), pharmaceutical compositions thereof are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate th e expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. All definitions are as in the application.

Подробнее
07-07-2004 дата публикации

Imidazole derivatives as antiinflammatory agents

Номер: EP1434579A1
Принадлежит: Tularik Inc

Compounds (I), pharmaceutical compositions thereof are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. All definitions are as in the application.

Подробнее
19-08-2014 дата публикации

Benzamide derivatives and uses related thereto

Номер: CA2611687C
Принадлежит: AMGEN INC

Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesit and related conditions and disorders: wherein R1, R2 , R3, R4, R5 , R6, R7, R9, R10, Rll, and R12 are defined as provided herein.

Подробнее
24-12-2008 дата публикации

Tricyclic inhibitors of hydroxysteroid dehydrogenases

Номер: CA2691309A1

The present invention provides tricyclic compounds according to formula (I): (I) where R1, R2, R3, W, X, Y, Z, m, n, and p are as defined in the description; as well as pharmaceutical compositions comprising the same, methods of use of the compounds and compositions of the invention for the treatment of conditions associated with hydroxysteroid dehydrogenases (e.g., 11 -HSD1), and the use of the compounds of the invention in the preparation of medicaments for the treatment of hydroxysteroid dehydrogenase-associated conditions.

Подробнее
08-12-2011 дата публикации

Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer

Номер: CA2799972A1
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
13-12-2012 дата публикации

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Номер: AU2011261263A1
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
14-12-2010 дата публикации

benzamide derivatives and their related use

Номер: BRPI0612993A2
Принадлежит: AMGEN INC

Patente de Invenção: DERIVADOS DE BENZAMIDA E SEU USO RELACIONADO. Derivados de benzamida de fórmulas I e II, e sais, solvatos, estereolsômeros e prô-fármacos farmaceuticamente aceitáveis dos mesmos, e composições farmacêuticas compreendendo os mesmos, são descritos e possuem utilidade terapêutica, particularmente no tratamento de diabetes, obesidade, e condições e distúrbios relacionados: em que R~1~, R~2~, R~3~, R~4~, R~5~, R~6~, R~7~, R~8~, R~9~, R~10~, R~11~ e R~12~ são definidos como aqui fornecido. Patent of Invention: BENZAMIDE DERIVATIVES AND ITS RELATED USE. Benzamide derivatives of formulas I and II, and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, and pharmaceutical compositions comprising them, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and conditions and disorders. Related: where R ~ 1 ~, R ~ 2 ~, R ~ 3 ~, R ~ 4 ~, R ~ 5 ~, R ~ 6 ~, R ~ 7 ~, R ~ 8 ~, R ~ 9 ~, R ~ 10 ~, R ~ 11 ~ and R ~ 12 ~ are defined as provided herein.

Подробнее
06-06-2002 дата публикации

Sulfonated diarylrhodamine dyes as fluorescent labels

Номер: WO2002044416A2
Принадлежит: Applera Corporation

Sulfonated diarylrhodamine compounds are useful as fluorescent labels of nucleosides, nucleotides, polynucleotides, and polypeptides. The compounds find particular application in the area of fluorescent nucleic acid analysis, e.g., automated DNA sequencing and fragment analysis, detection of probe hybridization in hybridization arrays, detection of nucleic acid amplification products, and the like.

Подробнее
01-06-2013 дата публикации

PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

Номер: MA34342B1
Принадлежит: AMGEN INC

La présente invention a pour objet des composés inhibiteurs de MDM2 de Formule (I), dans laquelle les variables sont définies ci-dessus, lesquels composés sont utiles en tant qu'agents thérapeutiques, en particulier pour le traitement de cancers. La présente invention concerne aussi des compositions pharmaceutiques qui contiennent un inhibiteur de MDM2. The subject of the present invention is MDM2 inhibiting compounds of Formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, in particular for the treatment of cancers. The present invention also relates to pharmaceutical compositions which contain an MDM2 inhibitor.

Подробнее
23-05-2019 дата публикации

Inhibitors of glucocorticoid receptor

Номер: AU2017339510A1
Принадлежит: Oric Pharmaceuticals Inc

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
15-12-2005 дата публикации

Arylsulfonamides and uses as hydroxysteroid dehydrogenase

Номер: AU2005250336A1
Принадлежит: AMGEN INC

Подробнее
12-04-2018 дата публикации

Inhibitors of glucocorticoid receptor

Номер: CA3039636A1
Принадлежит: Oric Pharmaceuticals Inc

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
28-07-2020 дата публикации

Inhibitors of glucocorticoid receptor

Номер: US10723759B2
Принадлежит: Oric Pharmaceuticals Inc

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
04-04-2013 дата публикации

Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer

Номер: WO2013049250A1
Принадлежит: Amgen Inc.

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
28-12-2021 дата публикации

PIPERIDINONE DERIVATIVE COMPOUND AS A MDM2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Номер: BR112012030923B1
Принадлежит: AMGEN INC

COMPOSTO DERIVADO DE PIPERIDINONA COMO INIBIDOR DE MDM2 E COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO. A presente invenção fornece compostos inibidores de MDM2 de fórmula (I), em que as variáveis são definidas acima, cujos compostos são úteis como agentes terapêuticos, particularmente para o tratamento de cânceres. A presente invenção também está relacionada a composições farmacêuticas que contêm um inibidor de MDM2. PIPERIDINONE DERIVATIVE COMPOUND AS A MDM2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME. The present invention provides MDM2 inhibitor compounds of formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
29-04-2008 дата публикации

Aryl sulfonamide compounds and uses related thereto

Номер: US7365075B2
Принадлежит: AMGEN INC

The present invention provides Aryl Sulfonamide Compounds having the formula: and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.

Подробнее
14-03-2017 дата публикации

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Номер: US9593129B2
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
22-02-2022 дата публикации

Piperidinone-derived compounds as mdm2 inhibitors for the treatment of cancer, pharmaceutical composition and use of said compound

Номер: BR122020013151B1
Принадлежит: AMGEN INC

A presente invenção fornece compostos inibidores de MDM2 de fórmula (I), em que as variáveis são definidas acima, cujos compostos são úteis como agentes terapêuticos, particularmente para o tratamento de cânceres. A presente invenção também está relacionada a composições farmacêuticas que contêm um inibidor de MDM2. The present invention provides MDM2 inhibitor compounds of formula (I), wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
31-01-2008 дата публикации

Sulfonated diarylrhodamine dyes

Номер: AU2008200036A1
Принадлежит: Applera Corp

Подробнее
28-08-2020 дата публикации

Inhibitors of glucocorticoid receptor

Номер: NZ753142A
Принадлежит: Oric Pharmaceuticals Inc

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein is a substituted steroidal derivative compound of the formula depicted, and pharmaceutical compositions comprising said compound. The subject compound and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
20-10-2009 дата публикации

Benzamide derivatives and uses related thereto

Номер: US7605289B2
Принадлежит: AMGEN INC

Benzamide derivatives of formula I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are defined as provided herein.

Подробнее
28-12-2006 дата публикации

Benzamide derivatives and uses related thereto

Номер: WO2006138508A2
Принадлежит: Amgen Inc.

Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesit and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, Rll, and R12 are defined as provided herein.

Подробнее
01-08-2012 дата публикации

Arylsulfonamides and uses as hydroxysteroid dehydrogenase

Номер: EP1753421B1
Принадлежит: AMGEN INC

Arylsulfonamide compounds of formula (I) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders.

Подробнее
19-04-2016 дата публикации

Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.

Номер: MX2015010619A
Принадлежит: AMGEN INC

La invención actual proporciona compuestos inhibidores de MDM2 de la Fórmula I, o las sales farmacéuticamente aceptables de los mismos, (ver Fórmula) en donde las variable se definen anteriormente, cuyos compuestos son útiles como agentes terapéuticos, particularmente para el tratamiento de cánceres. La invención actual también se refiere a composiciones farmacéuticas que contienen un inhibidor de MDM2.

Подробнее
17-09-2008 дата публикации

Diaza heterocyclic sulfonamide derivatives and their uses

Номер: EP1968962A2
Принадлежит: AMGEN INC

Diaza heterocyclic sulfonamide derivatives according to formula I have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: I where R7, R8, R9, R10, R11, R12, R13, X, Y1, Y2, m, and n are set forth in the description.

Подробнее
21-06-2007 дата публикации

Diaza heterocyclic sulfonamide derivatives and their uses

Номер: WO2007070506A2
Принадлежит: Amgen Inc.

Diaza heterocyclic sulfonamide derivatives according to formula I have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: I where R7, R8, R9, R10, R11, R12, R13, X, Y1, Y2, m, and n are set forth in the description.

Подробнее
29-03-2016 дата публикации

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Номер: US9296736B2
Принадлежит: AMGEN INC

The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Подробнее
18-07-2017 дата публикации

Application interface motion control method, device, and terminal device

Номер: BR112015018453A2
Автор: Li Weixing, SUN Daqing, Zhu Cai
Принадлежит: Xiaomi Inc

abstract provided are a method, apparatus and terminal device for controlling movement of an application interface, belonging to the field of interface control. the method comprises: capturing a first touch operation; when a second touch operation being captured in the capturing process of the first touch operation, determining the movement direction and movement distance of the second touch operation; and controlling the application interface to move a distance equal to the movement distance of the second touch operation along the movement direction of the second touch operation. by adopting the technical solutions provided by the disclosure, the application interface is controlled to move according to the movement direction and the movement distance of the second touch operation captured during the capturing process of the first touch operation, for enabling the application interface originally moved page by page to freely move, thus user browsing is more convenient. fig.1 tradução do resumo resumo patente de invenção: "método, aparelho e dispositivo terminal para controle de movimento de interface de aplicativo". a presente invenção refere-se a um método, um aparelho e um dispositivo terminal para controle do movimento de uma interface de aplicativo, referente ao campo de controle de interface. o método compreende: a captura de uma primeira operação de toque; quando uma segunda operação de toque é capturada no processo de captura da primeira operação de toque, a determinação da direção de movimento e da distância de movimento da segunda operação de toque; e o controle da interface de aplicativo para se mover por uma distância igual à distância de movimento da segunda operação de toque ao longo da direção de movimento da segunda operação de toque. pela adoção da solução técnica provida pela exposição, a interface de aplicativo é controlada para se mover de acordo com a direção de movimento e a distância de movimento da segunda operação de toque capturada ...

Подробнее
30-12-2011 дата публикации

PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT

Номер: UY33430A
Принадлежит: AMGEN INC

La presente invención proporciona compuestos de inhibidor MDM2 de la Fórmula I,en donde las variables se definen arriba, cuyos compuestos son útiles como agentes terapéuticos, particularmente para el tratamiento de cánceres. La presente invención también se refiere a composiciones farmacéuticas que contienen un inhibidor MDM2 .

Подробнее
29-04-2021 дата публикации

Inhibitors of glucocorticoid receptor

Номер: AU2021202016A1
Принадлежит: Oric Pharmaceuticals Inc

The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Подробнее
17-12-2020 дата публикации

Powder composition

Номер: WO2020248090A1
Принадлежит: Wacker Chemie AG

A powder composition comprising 30-60% of redispersible polymer powder, 5-30% of cement, 20-70% of filler and 0-8% of additives. The powder composition is featured by excellent adhesion properties when used for tile laying, especially adhesion property after storage under water immersion condition.

Подробнее
13-03-2023 дата публикации

Inhibidores de cd73.

Номер: MX2023002507A
Принадлежит: Oric Pharmaceuticals Inc

En la presente se describen inhibidores de CD73 y las composiciones farmacéuticas que comprenden estos compuestos. Los compuestos y composiciones de la invención son útiles para el tratamiento de cáncer, infecciones y enfermedades neurodegenerativas.

Подробнее
13-12-2023 дата публикации

Cdk inhibitor

Номер: EP4289835A1
Автор: Daqing Sun, Xiaoxia YAN

A compound serving as a selective CDK inhibitor, a pharmaceutical composition containing same, a useful intermediate for preparing the compound, and a use of the compound for preparing a drug for the treatment of cell proliferative diseases, such as cancer. The compound has the structure shown in formula (I-A).

Подробнее
02-02-2023 дата публикации

Novel parp7 inhibitor and use thereof

Номер: CA3226796A1

Disclosed are a compound serving as a PARP7 inhibitor, and a use thereof in preparing a drug for treating relevant diseases. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer.

Подробнее